Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

119 results about "NS5B" patented technology

Nonstructural protein 5B (NS5B) is a viral protein found in the hepatitis C virus (HCV). It is an RNA-dependent RNA polymerase, having the key function of replicating HCV's viral RNA by using the viral positive RNA strand as a template to catalyze the polymerization of ribonucleoside triphosphates (rNTP) during RNA replication. Several crystal structures of NS5B polymerase in several crystalline forms have been determined based on the same consensus sequence BK (HCV-BK, genotype 1). The structure can be represented by a right hand shape with fingers, palm, and thumb. The encircled active site, unique to NS5B, is contained within the palm structure of the protein. Recent studies on NS5B protein genotype 1b strain J4’s (HC-J4) structure indicate a presence of an active site where possible control of nucleotide binding occurs and initiation of de-novo RNA synthesis. De-novo adds necessary primers for initiation of RNA replication.

In vitro activity measuring method for hepatitis C virus RNA depending RNA polymerase and application thereof

The invention provides a detecting method and an application of the extraneous activity of the RNA polymerase relied on by the hepatitis C virus RNA, which relates to an secure and practical establishing method for the detection of the activity extraneous detection of the RNA polymerase relied on by the hepatitis C virus RNA, and the application relates to the genetic engineering technology and the nanometer segregation enrichment and RNA related technology field. The invention expresses the soluble NS5B protein through the utilization of the genetic engineering technology, and prepares the nanometer magnetic particle. One end of a RNA template is fixed on the nanometer magnetic particle, and added in the 96 hole reaction plate micromesh, and added with NS5B protein to compose a RNA duplication system, and a duplicated RNA double chain on the nanometer magnetic particle is mixed with marked biological elements. After the RNA is duplicated, the nanometer magnetic particle is attached at the micromesh bottom through an external magnetic field magnet, after repeatedly cleaning and attaching, the nanometer magnetic particle is combined with the marked combining factor of the horse radish peroxidase, after attaching and cleaning, the substrate constant of the horse radish peroxidase is added to develop color. New NS5B protease activity inhibitor can be screened from a traditional Chinese storeroom and a compound storeroom by the established method.
Owner:李越希

Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto

InactiveUS20080182895A1Reduce sensitivityReduced and minimal and no susceptibilityBiocideMicrobiological testing/measurementHepatitis c rnaTreatment resistant
The present invention provides methods of decreasing the frequency of emergence, decreasing the level of resistance, and delaying the emergence of a treatment-resistant Hepatitis C viral infection, by administering to a subject, either in combination or in series, an inhibitor of the Hepatitis C RNA-dependent RNA polymerase NS5B, e.g., a benzofuran, such as 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide (HCV-796), and at least one additional anti-Hepatitis C agent, e.g., a ribavirin product or an immunomodulator, such as an interferon product. Additionally, the invention relates to methods of monitoring the course of treatment of a Hepatitis C viral infection, methods of monitoring and prognosing a Hepatitis C viral infection, and methods of identifying an individual with a decreased likelihood of responding to an anti-Hepatitis C viral therapy. These methods use the sequence and/or structure of the Hepatitis C RNA-dependent RNA polymerase NS5B to identify the emergence of a treatment-resistant Hepatitis C viral infection, particularly a benzofuran (e.g., HCV-796) treatment-resistant Hepatitis C viral infection.
Owner:WYETH LLC +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products